Cited by 135Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingNerve injury and regeneration

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons

Porritt, M.J., Batchelor, P.E., Howells, D.W·2005·Experimental Neurology

DOI 10.1016/j.expneurol.2004.11.030

Open this paper in CoChat — free account

Abstract

Brain derived neurotrophic factor (BDNF) expression is significantly reduced in the Parkinson's disease substantia nigra. This neurotrophin has potent affects on dopaminergic neuron survival protecting them from the neurotoxins MPTP and 6-hydroxydopamine (6-OHDA) commonly used to create animal models of Parkinson's disease and also promoting dopaminergic axonal sprouting. In this study, we demonstrate that an antisense oligonucleotide infusion (200 nM for 28 days) to prevent BDNF production in the substantia nigra of rats mimics many features of the classical animal models of Parkinson's disease. 62% of antisense treated rats rotate (P < or = 0.05) in response to dopaminergic receptor stimulation by apomorphine. 40% of substantia nigra pars compacta tyrosine hydroxylase immunoreactive neurons are lost (P < or = 0.00001) and dopamine uptake site density measured by (3)H-mazindol autoradiography is reduced by 34% (P < or = 0.005). Loss of haematoxylin and eosin stained nigral neurons is significant (P < or = 0.0001) but less extensive (34%). These observations indicate that loss of BDNF expression leads both to down regulation of the dopaminergic phenotype and to dopaminergic neuronal death. Therefore, reduced BDNF mRNA expression in Parkinson's disease substantia nigra may contribute directly to the death of nigral dopaminergic neurons and the development of Parkinson's disease.

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2004.11.030

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system
Ungerstedt, U., & Arbuthnott, G. W. (1970) · Brain Research · doi:10.1016/0006-8993(70)90187-3 · Cited by 1,995
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,503
Adipsia and Aphagia after 6‐Hydroxydopamine Induced Degeneration of the Nigro‐striatal Dopamine System
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb11001.x · Cited by 1,294
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments
Schwarting, R. K. W., & Huston, J. P. (1996) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00040-8 · Cited by 741
Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor
Batchelor, P., Liberatore, G. T., Wong, J. Y. F., Porritt, M. J., Frerichs, F., Donnan, G. A., & Howells, D. W. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-05-01708.1999 · Cited by 576
Self-citation
Human and rat brain-derived neurotrophic factor and neurotrophin-3: Gene structures, distributions, and chromosomal localizations
Maisonpierre, P. C., Beau, M. M. L., Espinosa, R., Ip, N. Y., Belluscio, L., de la Monte, S. M., Squinto, S. P., Furth, M. E., & Yancopoulos, G. D. (1991) · Genomics · doi:10.1016/0888-7543(91)90436-i · Cited by 514
Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra
Howells, D. W., Porritt, M. J., Wong, J. Y. F., Batchelor, P. E., Kalnins, R., Hughes, A. J., & Donnan, G. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7483 · Cited by 513
Self-citation
BDNF and NT-4/5 Prevent Atrophy of Rat Rubrospinal Neurons after Cervical Axotomy, Stimulate GAP-43 and Tα1-Tubulin mRNA Expression, and Promote Axonal Regeneration
Kobayashi, N., Fan, D.-P., Giehl, K. M., Bedard, A. M., Wiegand, S. J., & Tetzlaff, W. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-24-09583.1997 · Cited by 476
Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression
Eisch, A. J., Bolaños, C. A., de Wit, J., Simonak, R. D., Pudiak, C. M., Barrot, M., Verhaagen, J., & Nestler, E. J. (2003) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.003 · Cited by 420

Show all 56 references

Sorted by citations

Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504
Brain-Derived Neurotrophic Factor Is Required for the Establishment of the Proper Number of Dopaminergic Neurons in the Substantia Nigra Pars Compacta
Baquet, Z. C., Bickford, P. C., & Jones, K. R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4601-04.2005 · Cited by 318
Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease
Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., & Teixeira, A. L. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5357-2 · Cited by 299
Neurotrophin signalling: novel insights into mechanisms and pathophysiology
Mitre, M., Mariga, A., & Chao, M. V. (2017) · Clinical Science · doi:10.1042/cs20160044 · Cited by 263
Gene Therapy for Parkinson’s Disease, An Update
Axelsen, T. M., & Woldbye, D. P. D. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181331 · Cited by 185
Circulating Levels of Brain-Derived Neurotrophic Factor: Correlation with mood, Cognition and Motor Function
Teixeira, A. L., Barbosa, I. G., Diniz, B. S., & Kümmer, A. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.111 · Cited by 164
Brain‐derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt/β‐catenin signaling pathway
Chen, B., Wang, X., Wang, Z., Wang, Y., Chen, L., & Luo, Z. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23138 · Cited by 133
The T herapeutic P otential of E xercise to I mprove M ood, C ognition, and S l eep in P arkinson's D isease
Reynolds, G., Otto, M. W., Ellis, T. D., & Cronin‐Golomb, A. (2015) · Movement Disorders · doi:10.1002/mds.26484 · Cited by 144
Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease
Fumagalli, F., Racagni, G., & Riva, M. A. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500360 · Cited by 135
Up-Regulation of Neurotrophic Factors by Cinnamon and its Metabolite Sodium Benzoate: Therapeutic Implications for Neurodegenerative Disorders
Jana, A., Modi, K. K., Roy, A., Anderson, J. A. D., van Breemen, R. B., & Pahan, K. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9447-7 · Cited by 128
Interaction between BDNF Val66Met and Dopamine Transporter Gene Variation Influences Anxiety-Related Traits
Hünnerkopf, R., Strobel, A., Gutknecht, L., Brocke, B., & Lesch, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301383 · Cited by 133
Unfolding the Role of BDNF as a Biomarker for Treatment of Depression
Rana, T., Behl, T., Sehgal, A., Srivastava, P., & BUNGAU, S. G. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01754-x · Cited by 136
Integral Characterization of Defective BDNF/TrkB Signalling in Neurological and Psychiatric Disorders Leads the Way to New Therapies
Tejeda, G., & Díaz-Guerra, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020268 · Cited by 126
Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB
Villani, G. R. D., Gargiulo, N., Faraonio, R., Castaldo, S., Reyero, E. G. Y., & Natale, P. D. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21134 · Cited by 126
MPTP‐induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF‐TrkB pathway
Zhu, G., Li, J., He, L., Wang, X., & Hong, X. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13061 · Cited by 118
Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: A systematic review and meta-analysis
Rahmani, F., Saghazadeh, A., Rahmani, M., Teixeira, A. L., Rezaei, N., Aghamollaii, V., & Ardebili, H. E. (2018) · Brain Research · doi:10.1016/j.brainres.2018.10.006 · Cited by 119
Dopamine D3 receptor agonists for protection and repair in Parkinson's disease
Joyce, J. N., & Millan, M. J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.11.004 · Cited by 108
Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease
Hou, L., Chen, W., Liu, X., Qiao, D., & Zhou, F.-M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00358 · Cited by 112
Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts
van Thriel, C., Westerink, R. H. S., Beste, C., Bale, A. S., Lein, P. J., & Leist, M. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.10.002 · Cited by 107
Involvement of BDNF in age-dependent alterations in the hippocampus
Halbach, O. V. B. U. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00036 · Cited by 103
Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways
Mangano, E. N., Litteljohn, D., So, R., Nelson, E., Peters, S., Bethune, C., Bobyn, J., & Hayley, S. P. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.016 · Cited by 96
Pitx3 Is a Critical Mediator of GDNF-Induced BDNF Expression in Nigrostriatal Dopaminergic Neurons
Peng, C., Aron, L., Klein, R., Li, M., Wurst, W., Prakash, N., & Le, W. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0898-11.2011 · Cited by 95
Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease
Fang, F., Yang, W., Florio, J. B., Rockenstein, E. M., Spencer, B. J., Orain, X., Dong, S. X., Li, H., Chen, X., Sung, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04232-4 · Cited by 94
Irisin, an exercise-induced bioactive peptide beneficial for health promotion during aging process
Zhang, H., Wu, X., Liang, J., Kirberger, M., & Chen, N. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101680 · Cited by 88
Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis
Jiang, L., Zhang, H., Wang, C., Ming, F., Shi, X., & Yang, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.07.010 · Cited by 88
Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease
Mangano, E. N., Peters, S., Litteljohn, D., So, R., Bethune, C., Bobyn, J., Clarke, M., & Hayley, S. P. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.02.011 · Cited by 75
Induction of GDNF and BDNF by hRheb(S16H) Transduction of SNpc Neurons: Neuroprotective Mechanisms of hRheb(S16H) in a Model of Parkinson’s Disease
Nam, J. H., Leem, E., Jeon, M.-T., Jeong, K. H., Park, J.-W., Jung, U. J., Kholodilov, N., Burke, R. E., Jin, B. K., & Kim, S. R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8729-2 · Cited by 76
Consequences of brain-derived neurotrophic factor withdrawal in CNS neurons and implications in disease
Mariga, A., Mitre, M., & Chao, M. V. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.009 · Cited by 80
PABPC1-induced stabilization of BDNF-AS inhibits malignant progression of glioblastoma cells through STAU1-mediated decay
Su, R., Ma, J., Zheng, J., Liu, X., Liu, Y., Ruan, X., Shen, S., Yang, C., Wang, D., Cai, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2267-9 · Cited by 74
Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson’s disease
Hernandez-Chan, N. G., Bannon, M. J., Orozco-Barrios, C. E., Escobedo, L., Zamudio, S., De la Cruz, F., Gongora-Alfaro, J. L., Armendáriz-Borunda, J., Reyes-Corona, D., Espadas-Alvarez, A. J., et al. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0166-7 · Cited by 73
Intranigral Transplantation of Epigenetically Induced BDNF-Secreting Human Mesenchymal Stem Cells: Implications for Cell-Based Therapies in Parkinson's Disease
Somoza, R., Juri, C., Baes, M., Wyneken, U., & Rubio, F. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.06.006 · Cited by 72
Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease
Liu, M., Xue, Y., Liu, C., Liu, Y.-H., Diao, H., Wang, Y., Pan, Y.-P., & Chen, L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00835 · Cited by 72
Maternal treadmill exercise during pregnancy decreases anxiety and increases prefrontal cortex VEGF and BDNF levels of rat pups in early and late periods of life
Aksu, İ., Baykara, B., Özbal, S., Çeti̇n, F., Şişman, A. R., Dayı, A., Gençoğlu, C., Taş, A., Büyük, E., Arda, S. G., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.091 · Cited by 71
Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons
Caudal, D., Alvarsson, A., Björklund, A., & Svenningsson, P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.09.002 · Cited by 73
Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid β
Tanqueiro, S. R., Ramalho, R. M., Rodrigues, T. M., Lopes, L. V., Sebastião, A. M., & Diógenes, M. J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00237 · Cited by 67
Leptin as a neuroprotective agent
Tang, B. L. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.063 · Cited by 66
Potential Therapeutic Effects of Neurotrophins for Acute and Chronic Neurological Diseases
Cai, J., Hua, F., Yuan, L., Tang, W., Lu, J., Yu, S., Wang, X., & Hu, Y. (2014) · BioMed Research International · doi:10.1155/2014/601084 · Cited by 66
Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents
Nie, S., Yan, X., Chen, G., Ma, K., Han, C., Guo, Z., Zhang, Z., Ye, K., & Cao, X. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.016 · Cited by 65
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases
Gibrat, C., & Cicchetti, F. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.023 · Cited by 68
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV
Yang, L., Calingasan, N. Y., Lorenzo, B. J., & Beal, M. F. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.010 · Cited by 65
D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
Li, Y., Liu, W., Li, L., & Hölscher, C. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.050 · Cited by 62
Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications
Heckman, P. R. A., van Duinen, M. A., Bollen, E., Nishi, A., Wennogle, L. P., Blokland, A., & Prickaerts, J. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw030 · Cited by 63
Neurorestoration by physical exercise: Moving forward
Zigmond, M. J., Cameron, J. L., Hoffer, B. J., & Smeyne, R. J. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70046-3 · Cited by 60
Genetic deletion of vesicular glutamate transporter in dopamine neurons increases vulnerability to MPTP-induced neurotoxicity in mice
Shen, H., Marino, R. A. M., McDevitt, R. A., Bi, G.-H., Chen, K., Madeo, G., Lee, P.-T., Liang, Y., De Biase, L. M., Su, T.-P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800886115 · Cited by 58
Novel D3 dopamine receptor‐preferring agonist D‐264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine and lactacystin
Li, C., Biswas, S., Li, X., Dutta, A. K., & Le, W. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22405 · Cited by 56
Long noncoding RNA BDNF-AS is a potential biomarker and regulates cancer development in human retinoblastoma
Shang, W., Yang, Y., Zhang, J., & Wu, Q. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.134 · Cited by 56
Brain-Derived Neurotrophic Factor: A Novel Dynamically Regulated Therapeutic Modulator in Neurological Disorders
Sharma, V., Singh, T. G., Kaur, A., Mannan, A., & Dhiman, S. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03755-1 · Cited by 58
Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum
Chase, T. D., CARREY, N. J., Soo, E. C., & Wilkinson, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.035 · Cited by 51
Maternal exercise decreases maternal deprivation induced anxiety of pups and correlates to increased prefrontal cortex BDNF and VEGF
Uysal, N., Şişman, A. R., Dayı, A., Aksu, İ., Çeti̇n, F., Gençoğlu, C., Taş, A., & Büyük, E. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.10.039 · Cited by 48
Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats
Sharma, S., & Deshmukh, R. R. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.12.008 · Cited by 48
Fibroblast growth factor 9 prevents MPP+‐induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro
Huang, J.-Y., Hong, Y., & Chuang, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06061.x · Cited by 48
Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders
Sharma, S., Kumar, K., Deshmukh, R. R., & Sharma, P. L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.038 · Cited by 51
FGF9-induced changes in cellular redox status and HO-1 upregulation are FGFR-dependent and proceed through both ERK and AKT to induce CREB and Nrf2 activation
Chuang, J., Huang, J.-Y., Tsai, S., Sun, H. S., Yang, S., Chuang, P., Huang, B., & Ching, C. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.08.011 · Cited by 44
Neurotrophic Factors in Neurodegenerative Disorders
Fumagalli, F., Molteni, R., Calabrese, F., Maj, P. F., Racagni, G., & Riva, M. A. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00004 · Cited by 42
Elevated P75NTR expression causes death of engrailed-deficient midbrain dopaminergic neurons by Erk1/2 suppression
Alavian, K. N., Sgadó, P., Alberi, L. A., Subramaniam, S., & Simon, H. H. (2009) · Neural Development · doi:10.1186/1749-8104-4-11 · Cited by 44
Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease
Chang, E., & Wang, J. (2021) · Brain and Behavior · doi:10.1002/brb3.2251 · Cited by 41
Serum BDNF discriminates Parkinson’s disease patients with depression from without depression and reflect motor severity and gender differences
Huang, Y., Huang, C., Zhang, Q., Wu, W., & Sun, J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10299-3 · Cited by 43
The Pleiotropic Potential of BDNF beyond Neurons: Implication for a Healthy Mind in a Healthy Body
Rosa, M. C. D., Zimbone, S., Saab, M. W., & Tomasello, M. F. (2021) · Life · doi:10.3390/life11111256 · Cited by 41
Use of growth factors for the treatment of Parkinson’s disease
Yasuda, T., & Mochizuki, H. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.55 · Cited by 41
New Frontiers in Neurodegeneration and Regeneration Associated with Brain-Derived Neurotrophic Factor and the rs6265 Single Nucleotide Polymorphism
Szarowicz, C. A., Steece‐Collier, K., & Caulfield, M. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23148011 · Cited by 43
Biogenic Amines in Rett Syndrome: The Usual Suspects
Roux, J., & Villard, L. (2009) · Behavior Genetics · doi:10.1007/s10519-009-9303-y · Cited by 37
Progesterone treatment decreases traumatic brain injury induced anxiety and is correlated with increased serum IGF-1 levels; prefrontal cortex, amygdala, hippocampus neuron density; and reduced serum corticosterone levels in immature rats
Baykara, B., Aksu, İ., Büyük, E., Kıray, M., Sisman, A., Baykara, B., Dayı, A., Taş, A., Ozdemir, D., Arda, M., et al. (2013) · Biotechnic & Histochemistry · doi:10.3109/10520295.2013.769630 · Cited by 38
Epigenetic Biomarkers as Diagnostic Tools for Neurodegenerative Disorders
Martínez-Iglesias, O. A., Naidoo, V., Cacabelos, N., & Cacabelos, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010013 · Cited by 41
Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection
Kincses, Z. T., & Vécsei, L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00150.x · Cited by 39
Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
Singh, S. T., Ahmad, R., Mathur, D., Sagar, R., & Krishana, B. (2006) · PubMed · Cited by 36
Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets
Souza, E. B. D., Cload, S. T., Pendergrast, P. S., & Sah, D. W. Y. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.115 · Cited by 34
Rola mózgowego czynnika neurotroficznego (BDNF) w procesach neurodegeneracji oraz w mechanizmach neuroregeneracji wywołanej wzmożoną aktywnością fizyczną
Malczynska-Sims, P., Piotrowicz, Z., Drabarek, D., Langfort, J., & Chalimoniuk, M. (2019) · Postępy Biochemii · doi:10.18388/pb.2019_251 · Cited by 36
The TrkB-Positive Dopaminergic Neurons are Less Sensitive to MPTP Insult in the Substantia Nigra of Adult C57/BL Mice
Ding, Y., Xia, Y., Jiao, X., Duan, L. N., Yu, J., Wang, X., & Chen, L.-W. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0491-5 · Cited by 32
Brain-Derived Neurotrophic Factor (BDNF) in Mechanisms of Autistic-like Behavior in BTBR Mice: Crosstalk with the Dopaminergic Brain System
Ilchibaeva, T. V., Tsybko, A. S., Lipnitskaya, M., Eremin, D. V., Milutinovich, K. S., Naumenko, V. S., & Popova, N. K. (2023) · Biomedicines · doi:10.3390/biomedicines11051482 · Cited by 30
Inhibition of BDNF production by MPP + through up-regulation of miR-210-3p contributes to dopaminergic neuron damage in MPTP model
Zhang, S., Chen, S., Liu, A., Wan, J., Tang, L., Zheng, N., & Xiong, Y. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.10.014 · Cited by 29
An experimental study on intracerebroventricular transplantation of human amniotic epithelial cells in a rat model of Parkinson's disease
Yang, X., Song, L., Wu, N., Liu, Z., Xue, S., & Hui, G. (2010) · Neurological Research · doi:10.1179/016164110x12681290831207 · Cited by 28
Role of orexin in pathogenesis of neurodegenerative parkinsonisms
Alster, P., Madetko‐Alster, N., Otto‐Ślusarczyk, D., Migda, A. M., Migda, B., Struga, M., & Friedman, A. (2023) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2023.0044 · Cited by 28
Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease
Sano, H., Murata, M., & Nambu, A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13116 · Cited by 25
BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the “weaver” mouse, a genetic model of dopamine-denervation, acting through the TrkB neurotrophin receptor
Botsakis, K., Mourtzi, T., Panagiotakopoulou, V., Vreka, M., Stathopoulos, G. T., Pediaditakis, I., Charalampopoulos, I., Gravanis, A., Delis, F., Antoniou, K., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.043 · Cited by 25
Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease
Churchill, M. J., Cantu, M. A., Kasanga, E. A., Moore, C., Salvatore, M. F., & Meshul, C. K. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.06.006 · Cited by 25
Targeting brain‐derived neurotrophic factor in the treatment of neurodegenerative diseases: A review
Wang, D., Lang, Z., Wei, S., Wang, W., & Zhang, H. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.43 · Cited by 31
Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities
Simion, V., Nadim, W. D., Bénédetti, H., Pichon, C., Morisset‐Lopez, S., & Baril, P. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160630210422 · Cited by 26
Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein
Delic, V., Griffin, J. W. D., Zivkovic, S., Zhang, Y., Phan, T.-A., Gong, H., Chaput, D., Reynes, C., Dinh, V. B., Cruz, J., et al. (2017) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8448-8 · Cited by 25
Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain‐derived neurotrophic factor
Komnig, D., Dagli, T. C., Habib, P., Zeyen, T., Schulz, J. B., & Falkenburger, B. H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14575 · Cited by 24
Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease
Xu, Y., Yang, Y., Zhao, Z., Xu, M., Zhang, Y., Sheng, Y., Tian, J., & Xu, Z. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.680765 · Cited by 25
Adolescent social isolation influences cognitive function in adult rats.
Shao, F., Xiao, H., Shao, S., & Wang, W. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.11.008 · Cited by 23
Activation of BDNF-AS/ADAR/p53 Positive Feedback Loop Inhibits Glioblastoma Cell Proliferation
Lv, X., Gu, C., & Guo, S. (2020) · Neurochemical Research · doi:10.1007/s11064-019-02943-w · Cited by 22
Targeted deletion of GD3 synthase protects against MPTP ‐induced neurodegeneration
Akkhawattanangkul, Y., Maiti, P., Xue, Y., Aryal, D., Wetsel, W. C., Hamilton, D., Fowler, S. C., & McDonald, M. P. (2017) · Genes Brain & Behavior · doi:10.1111/gbb.12377 · Cited by 22
Protein tyrosine phosphatase inhibition reduces degeneration of dopaminergic substantia nigra neurons and projections in 6‐OHDA treated adult rats
Yang, P., Dankowski, A., & Hagg, T. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05384.x · Cited by 22
Comparative pharmacodynamic study delineating the efficacy of amantadine loaded nano-emulsified organogel via intranasal versus transdermal route in rotenone-induced Parkinson's disease rat model
Farag, M. M., El‐Nassan, H. B., Merey, H. A., Eltanany, B. M., Galal, M. M., Wadie, W., El-Tanbouly, D. M., Khattab, M. A., Rashed, L. A., & ElMeshad, A. N. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104765 · Cited by 21
Age-related gene expression changes in substantia nigra dopamine neurons of the rat
Parkinson, G. M., Dayas, C. V., & Smith, D. W. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.06.002 · Cited by 21
Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease
Luthra, N., Mehta, N., Munoz, M. J., Fantuzzi, G., Lamotte, G. J., Haus, J. M., McFarland, N. R., Tansey, M. G., González-Latapí, P., Caraveo, G., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01042-8 · Cited by 24
Long noncoding RNA BDNF-AS is downregulated in cervical cancer and has anti-cancer functions by negatively associating with BDNF
Zhang, H., Liu, C., Yan, T., Wang, J., & Liang, W. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.03.023 · Cited by 20
Studies of Depression-Related States in Animal Models of Parkinsonism
Schintu, N., Zhang, X., & Svenningsson, P. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-12076 · Cited by 21
Anxiety caused by traumatic brain injury correlates to decreased prefrontal cortex vegf immunoreactivity and neuron density in immature rats
Baykara, B., Çeti̇n, F., Baykara, B., Aksu, İ., Dayı, A., Kıray, M., Şişman, A. R., Özdemir, D., Arda, M. N., & Uysal, N. (2012) · Turkish Neurosurgery · doi:10.5137/1019-5149.jtn.5633-11.1 · Cited by 17
Psychological distress and lack of PINK1 promote bioenergetics alterations in peripheral blood mononuclear cells
Grigoruţă, M., Dagda, R. K., Díaz‐Sánchez, Á. G., & Martı́nez-Martı́nez, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66745-9 · Cited by 16
BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis
Mittal, V. A., Smolen, A., Dean, D. J., Pelletier‐Baldelli, A., Lunsford‐Avery, J. R., & Smith, A. K. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.018 · Cited by 17
Neurotrophic Support of Midbrain Dopaminergic Neurons
Halbach, O. V. B. U., & Unsicker, K. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-0322-8_7 · Cited by 15
Neurotrophin Signaling and Cell Survival
Manadas, B. J., Melo, C. V., Gomes, J. R., & Duarte, C. B. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_7 · Cited by 13
Steady Moderate Exercise Confers Resilience Against Neurodegeneration and Neuroinflammation in a Mouse Model of Parkinson’s Disease
Pałasz, E., Gąsiorowska, A., Drapich, P., Niewiadomski, W., & Niewiadomska, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031146 · Cited by 13
Ablation of serum response factor in dopaminergic neurons exacerbates susceptibility towards MPTP‐induced oxidative stress
Rieker, C., Schober, A., Bilbao, A., Schütz, G., & Parkitna, J. M. R. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08003.x · Cited by 12
Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease
Guo, C., Wang, T., Huang, H., Wang, X., Jiang, Y., & Li, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-59090-8 · Cited by 11

Authors: Porritt, M. J., Batchelor, P. E., & Howells, D. W.
Affiliations: The University of Melbourne (AU)
Corresponding author: Howells, D.W
ORCID: Porritt, M.J.
Batchelor, P.E.
Howells, D.W
Venue: Experimental Neurology
Publisher: Elsevier BV
Published: 2005-03
Volume: 192
Issue: 1
Pages: 226-234
ISSN: 0014-4886 (ISSN-L)
DOI: 10.1016/j.expneurol.2004.11.030
OpenAlex: W1985464631
Cited by: 135
References: 56
Citations by year: 2025: 7 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 4 · 2020: 8 · 2019: 3 · 2018: 10 · 2017: 9 · 2016: 6 · 2015: 10 · 2014: 5 · 2013: 6 · 2012: 11
FWCI: 4.06
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Experimental Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: Hospital Research Foundation
Austin Medical Research Foundation
National Health and Medical Research Council
National Medical Research Council
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords: brain-derived neurotrophic factor, substantia nigra pars compacta, dopaminergic neuron loss, Parkinson's disease, tyrosine hydroxylase, dopamine uptake, MPTP, 6-hydroxydopamine, apomorphine rotation, Parkinson's disease model
MeSH terms: Animals, Binding, Competitive, Cell Survival, Disease Models, Animal, Dopamine, Male, Mazindol, Nerve Degeneration, Neurons, Radioligand Assay, Receptors, Dopamine, RNA, Messenger, Substantia Nigra, Tyrosine 3-Monooxygenase, Down-Regulation, Oligonucleotides, Antisense, Cell Death, Rats, Sprague-Dawley, Neuroprotective Agents, Dopamine Uptake Inhibitors, Brain-Derived Neurotrophic Factor, Parkinsonian Disorders, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks